Comparative Pharmacology
Head-to-head clinical analysis: ARGATROBAN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARGATROBAN IN 0 9 SODIUM CHLORIDE versus MAGNESIUM SULFATE.
ARGATROBAN IN 0.9% SODIUM CHLORIDE vs MAGNESIUM SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Direct thrombin inhibitor that reversibly binds to the active site of thrombin, inhibiting fibrin formation, activation of coagulation factors V, VIII, and XIII, and platelet aggregation.
Magnesium sulfate acts as a physiological calcium channel blocker. It inhibits calcium influx into presynaptic nerve terminals, reducing acetylcholine release at the neuromuscular junction and decreasing muscle contraction. It also antagonizes NMDA receptors and stabilizes neuronal membranes.
Continuous IV infusion: 2 mcg/kg/min, adjusted to maintain aPTT 1.5-3 times baseline. Maximum initial infusion rate is 10 mcg/kg/min.
IV: Loading dose 4-6 g over 20-30 minutes, followed by maintenance infusion 1-2 g/hour for seizure prophylaxis in severe preeclampsia/eclampsia. IM: 4-8 g deep IM initially, then 4 g every 4 hours as needed.
None Documented
None Documented
Clinical Note
moderateMagnesium sulfate + Gatifloxacin
"The serum concentration of Gatifloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Rosoxacin
"The serum concentration of Rosoxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateMagnesium sulfate + Levofloxacin
"The serum concentration of Levofloxacin can be decreased when it is combined with Magnesium sulfate."
Clinical Note
moderateTerminal elimination half-life is 39–51 minutes in healthy subjects; prolonged to 181–269 minutes in patients with hepatic impairment. Clinical context: Short half-life allows rapid reversal of anticoagulation upon discontinuation.
Terminal elimination half-life approximately 4-6 hours in patients with normal renal function; prolonged to 12-24 hours or more in renal impairment, necessitating dose adjustment
Primarily hepatic (biliary) excretion: approximately 65% eliminated via bile into feces; renal excretion accounts for about 22% as unchanged drug and metabolites.
Primarily renal (90-95% as unchanged drug); minor biliary/fecal (<5%)
Category A/B
Category C
Electrolyte
Electrolyte
Magnesium sulfate + Trovafloxacin
"The serum concentration of Trovafloxacin can be decreased when it is combined with Magnesium sulfate."